A Capsida scientist at work in the company’s laboratory in Thousand Oaks. (courtesy photo) Thousand Oaks-based Capsida ...

Italian authorities released the director of a notorious detention camp who had been arrested in Turin on an ICC war crimes warrant. Italian police were acting on an arrest warrant from the ...

AbbVie Inc. will record a $3.5 billion charge after a schizophrenia drug it gained in the purchase of Cerevel Therapeutics Inc. failed in clinical trials. The experimental drug, emraclidine, failed to ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. The biotech company reported in November ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger from Leerink Partners maintained a Buy rating on the ...

AbbVie will clearly fight to keep its top-selling Humira (adalimumab) anti-inflammatory drug on the market for as long as possible – but it also has one eye on a possible successor that is ...

AbbVie ABBV underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by ...

THOUSAND OAKS, Calif., Jan. 7, 2025 /PRNewswire/ -- Capsida Biotherapeutics (“Capsida”) today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ...

Capsida Biotherapeutics yesterday revealed US pharma major AbbVie (NYSE: ABBV) has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. As a result, ...